Recurrence patterns after resection of retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative.
distant relapse
local relapse
overall survival
predictors
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
05
06
2019
accepted:
09
06
2019
pubmed:
28
6
2019
medline:
20
8
2019
entrez:
28
6
2019
Statut:
ppublish
Résumé
Resection of primary retroperitoneal sarcomas (RPS) has a high incidence of recurrence. This study aims to identify patterns of recurrence and its impact on overall survival. Adult patients with primary retroperitoneal soft tissue sarcomas who underwent resection in 2000-2016 at eight institutions of the US Sarcoma Collaborative were evaluated. Four hundred and ninety-eight patients were analyzed, with 56.2% (280 of 498) having recurrences. There were 433 recurrences (1-8) in 280 patients with 126 (25.3%) being locoregional, 82 (16.5%) distant, and 72 (14.5%) both locoregional and distant. Multivariate analyses revealed the following: Patient age P = .0002), tumor grade (P = .02), local recurrence (P = .0003) and distant recurrence (P < .0001) were predictors of disease-specific survival. The 1-, 3-, and 5-year survival rate for patients who recurred vs not was 89.6% (standard error [SE] 1.9) vs 93.5% (1.8), 66.0% (3.2) vs 88.4% (2.6), and 51.8% (3.6) vs 83.9% (3.3), respectively, P < .0001. Median survival was 5.3 years for the recurrence vs 11.3+ years for the no recurrence group (P < .0001). Median survival from the time of recurrence was 2.5 years. Recurrence after resection of RPS occurs in more than half of patients independently of resection status or perioperative chemotherapy and is equally distributed between locoregional and distant sites. Recurrence is primarily related to tumor biology and is associated with a significant decrease in overall survival.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Resection of primary retroperitoneal sarcomas (RPS) has a high incidence of recurrence. This study aims to identify patterns of recurrence and its impact on overall survival.
METHODS
METHODS
Adult patients with primary retroperitoneal soft tissue sarcomas who underwent resection in 2000-2016 at eight institutions of the US Sarcoma Collaborative were evaluated.
RESULTS
RESULTS
Four hundred and ninety-eight patients were analyzed, with 56.2% (280 of 498) having recurrences. There were 433 recurrences (1-8) in 280 patients with 126 (25.3%) being locoregional, 82 (16.5%) distant, and 72 (14.5%) both locoregional and distant. Multivariate analyses revealed the following: Patient age P = .0002), tumor grade (P = .02), local recurrence (P = .0003) and distant recurrence (P < .0001) were predictors of disease-specific survival. The 1-, 3-, and 5-year survival rate for patients who recurred vs not was 89.6% (standard error [SE] 1.9) vs 93.5% (1.8), 66.0% (3.2) vs 88.4% (2.6), and 51.8% (3.6) vs 83.9% (3.3), respectively, P < .0001. Median survival was 5.3 years for the recurrence vs 11.3+ years for the no recurrence group (P < .0001). Median survival from the time of recurrence was 2.5 years.
CONCLUSIONS
CONCLUSIONS
Recurrence after resection of RPS occurs in more than half of patients independently of resection status or perioperative chemotherapy and is equally distributed between locoregional and distant sites. Recurrence is primarily related to tumor biology and is associated with a significant decrease in overall survival.
Identifiants
pubmed: 31246290
doi: 10.1002/jso.25606
pmc: PMC6743490
mid: NIHMS1048686
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-347Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Wake Forest University
ID : NCI CCSG P30CA012197
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Surg Oncol. 2014 Jan;109(1):53-9
pubmed: 24155163
J Natl Compr Canc Netw. 2014 Apr;12(4):473-83
pubmed: 24717567
Cancer. 2017 Jun 1;123(11):1971-1978
pubmed: 28152173
J Surg Oncol. 2018 Jan;117(1):99-104
pubmed: 29193081
Ann Surg. 2016 Mar;263(3):593-600
pubmed: 25915910
Nat Rev Clin Oncol. 2018 Jul;15(7):443-458
pubmed: 29666441
Lancet Oncol. 2016 Jul;17(7):966-975
pubmed: 27210906
Am J Clin Oncol. 2005 Jun;28(3):310-6
pubmed: 15923806
Ann Oncol. 2014 Mar;25(3):735-742
pubmed: 24567518
Ann Surg Oncol. 2016 Oct;23(11):3531-3540
pubmed: 27480354
Surgery. 2018 Feb;163(2):318-323
pubmed: 28943041
J Clin Oncol. 2009 Jan 1;27(1):31-7
pubmed: 19047280
Ann Surg Oncol. 2010 Jun;17(6):1481-4
pubmed: 20401636
J Surg Oncol. 2016 Mar;113(3):270-6
pubmed: 26707028
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186
Cancer. 2018 Dec 1;124(23):4495-4503
pubmed: 30317543
Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1
pubmed: 14501502
J Clin Oncol. 2013 May 1;31(13):1649-55
pubmed: 23530096
J Clin Oncol. 2009 Jan 1;27(1):24-30
pubmed: 19047283